DUBLIN, Dec. 01, 2015 /PRNewswire/ --
Research and Markets (http://www.researchandmarkets.com/research/xkbpfx/spinal_muscular) has announced the addition of the "Spinal Muscular Atrophy Market - Pipeline Assessment, Size, Growth, Trends, and Forecast 2015 - 2023" report to their offering.
This report collates information from various government as well as corporate sources such as Europe and the U.S. clinical trial registries, World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), CureSMA, Families of SMA, PubMed, company press releases, annual reports and investor presentations. The analysis also considers inputs from industry experts and key opinion leaders with expertise in rare disease drug discovery, and marketing and sales experts.
In the pipeline analysis of spinal muscular atrophy (SMA) market report, market analysis and forecast has been provided for late stage (phase 3) candidates, while also includes thorough qualitative information for other candidates in early stage (phase 1 and phase 2). ISIS-SMNRx by Isis Pharmaceuticals is presently the only late stage candidate in spinal muscular atrophy pipeline, while three drugs are currently in phase 2 and three others in phase 1. These include Olesoxime (TRO19622), LMI070, RO6885247, CK-2127107, scAAV9.CB.SMN and RG3039.
Key players with potential candidates in clinical trials for treatment of spinal muscular atrophy have been profiled in the report. Each of the company profile provides details such as company overview, business overview, financial overview, product portfolio, business strategies, and recent developments."
Companies Mentioned:
- AveXis, Inc.
- Cytokinetics, Inc.
- F. Hoffmann-La Roche Ltd.
- Isis Pharmaceuticals, Inc.
- Novartis AG
- 3M Company
- Clariant
- Debiotech S.A.
- HzO, Inc.
- Nanotrons Corporation
- P2i Ltd.
- SLIPS Technologies, Inc.
- The Dow Chemical Company
- nanoShell Ltd.
Key Topics Covered:
Chapter 1 Introduction
Chapter 2 Executive Summary
Chapter 3 Pipeline Analysis: Spinal Muscular Atrophy Market Overview
Chapter 4: Pipeline Analysis: Spinal Muscular Atrophy
Chapter 5 Recommendation
Chapter 6 Company Profiles
For more information visit http://www.researchandmarkets.com/research/xkbpfx/spinal_muscular
Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net
